It is worth mentioning that due to its pro-angiogenic action, the BPC-157 peptide is able to regenerate damage caused by various factors, including damage induced by stress, mechanical injuries, or damage resulting from other diseases
Only 40% percent of patients with early stage HCC are eligible for potentially curative treatments (surgical resection, transplantation, local ablation), which prolong median survival times over 60 months ( c-Met Inhibitors So far, there are six Met inhibitors developed and they have been tested in 10 HCC clinical trials ( in vitro and in vivo trials ( Also, several clinical trials are (Table 1), including cabozanitinib, foretinib, cobazitinib, gefitinib, crizotinib, MSC2156119, AZD4547, MK2461, and INC280 ( TABLE 1 Drugs targeting HGF/c-Met in hepatocellular carcinoma patients
You can request the Certificate of Analysis for the specific batch you are using at any time
BPC-157 has shown a favorable safety profile in animal models, with no significant toxicity observed at therapeutic doses